LOGIN  |  REGISTER
Amneal Pharmaceuticals

Zynex Ranked in Forbes List of "America's Most Successful Small-Cap Companies 2024"

November 15, 2023 | Last Trade: US$8.18 0.04 -0.49

ENGLEWOOD, Colo., Nov. 15, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Company has been ranked within Forbes' list of America's Most Successful Small-Cap Companies for 2024. The 2024 Forbes list of America's Most Successful Small-Cap Companies can be found at www.forbes.com.

"We are honored to be included in Forbes' Most Successful Small-Cap Companies list for the fourth year in a row," said Thomas Sandgaard, CEO of Zynex. "We believe our emphasis on providing non-invasive patient solutions leads to consistent revenue and profitability growth that will allow Zynex to become the world's premier pain management provider."

The data used to analyze the companies on the list was compiled from FactSet. Forbes screened over 1,000 small cap companies and narrowed the list down to 389 of which had positive sales growth over the past twelve months and a share price of at least $5. The rankings are based on many factors, including earnings growth, sales growth, return on equity, and total stock return for the trailing twelve months and over the last five years.

About Zynex, Inc.

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
This email address is being protected from spambots. You need JavaScript enabled to view it.
+949 694 9594

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB